Safety & Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for

Status Completed

Clinical Trial Summary

A prospective, multisite study to evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® vaccination in pediatric patients 6-24 months of age who are being considered and/or evaluated for any solid organ transplant (heart, liver or kidney)

Clinical Trial Description

Primary Aim:

To measure the antibody response to ProQuad® vaccination given earlier than the current recommended age in patients from the age of 6 months to 24 months who are being considered and/or evaluated for any solid organ transplant (heart, liver or kidney) within the next five years. These subjects would not reach the recommended ages to receive the vaccine before the transplant.

Hypothesis:

The Investigator proposes the hypothesis that the proposed study population will mount a clinically significant response to two (2) doses of the ProQuad® vaccine.

Primary Endpoint:

With respect to expected outcomes, the work proposed is expected to provide tools for optimizing the ProQuad® vaccination strategy in this population.

Secondary Aim:

To determine the safety of ProQuad® vaccination in children aged 6 months to 24 months who are being considered and/or evaluated for any solid organ transplant (heart, liver, kidney).

Hypothesis :

The Investigator proposes the hypothesis that the study population will have similar safety profiles compared to children who receive the vaccine at the recommended ages.

Secondary Endpoint:

The secondary outcome measure is represented by the children in the study having either no adverse effects or minimal adverse effects from the ProQuad® vaccine. Adverse effects will be monitored via Electronic Medical Records (EMR) for Emergency Department (ED), hospital or clinic visits, follow-up phone calls to the family/subjects, as well as the vaccination report card that the parents/legal guardians of the participants in the study will complete for their child for 7 days after he/she receives each dose of the vaccine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02687763
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Completed
Phase	Early Phase 1
Start date	December 2015
Completion date	November 3, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03481322` - Low Sodium Cooking Study	N/A
Completed	`NCT00001638` - Magnetic Resonance Imaging of the Blood Vessels of the Heart
Completed	`NCT02376244` - The Health Impact of High Intensity Exercise Training With Intervals During Cardiac Rehabilitation	N/A
Completed	`NCT02523144` - Dexmedetomidine in Children Having Transthoracic Echocardiography	Phase 4
Completed	`NCT02277379` - Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery	N/A
Completed	`NCT02045641` - Pleural and Pericardial Effusion Following Open Heart Surgery	N/A
Completed	`NCT01871090` - Remote Device Interrogation In The Emergency Department	N/A
Active, not recruiting	`NCT01400490` - Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study	N/A
Completed	`NCT01192360` - Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease	Phase 3
Terminated	`NCT00935766` - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries	Phase 3
Completed	`NCT00745446` - The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation	N/A
Completed	`NCT00140816` - Dairy Products and Metabolic Effects (Norwegian Part)	N/A
Completed	`NCT00178620` - Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization	Phase 4
Completed	`NCT00013949` - Cardiovascular Vulnerability to Particulate Exposure	N/A
Completed	`NCT01952171` - The Genetic Basis of Congenital Heart Disease in Africa
Recruiting	`NCT02933892` - Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization	Phase 4
Withdrawn	`NCT02838355` - Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients	N/A
Completed	`NCT02923518` - Cardiac Screening of Middle Aged and Older Women and Men (Master Athletes)
Terminated	`NCT02282163` - Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography	Phase 3
Active, not recruiting	`NCT02260466` - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant — ProQuad®

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms